Lab services company Charles River Laboratories (NYSE: CRL) reported revenue ahead of Wall Street’s expectations in Q2 CY2026, but sales fell by 2.7% year on year to $1.00 billion. Its non-GAAP profit of $3.02 per share was 10.6% above analysts’ consensus estimates.

Is now the time to buy CRL? Find out in our full research report (it’s free for active Edge members).

StockStory’s Take

Charles River Laboratories’ second quarter results were shaped by recovering biopharmaceutical demand and the impact of portfolio streamlining. Management highlighted that the rebound was most evident in the Discovery and Safety Assessment (DSA) segment, where net book-to-bill reached a four-year high and organic revenue growth turned positive for the first time since 2023. CEO Birgit Girshick pointed to an uptick in proposal activity and improved funding for small and midsize biotech clients as critical factors that helped stabilize revenues, even as North American academic and government spending remained subdued. The divestiture of non-core businesses provided an immediate operating margin benefit, with the Manufacturing segment seeing notable improvement.

Looking ahead, Charles River Laboratories’ updated guidance rests on expectations for further improvement in DSA demand, greater operational efficiencies, and the full-year impact of recent divestitures. Management believes the company’s unique positioning—particularly its integrated supply of nonhuman primates (NHPs) and expanded bioanalytical capacity—will support acceleration in organic revenue growth during the second half of the year. CFO Glenn Coleman cautioned that margin gains from lower NHP sourcing costs will be most pronounced in the fourth quarter, while the full benefit of capacity investments in bioanalysis and digital pathology is expected to emerge in 2027. The team emphasized that continued modernization and expansion of core testing capabilities are central to sustaining momentum.

Key Insights from Management’s Remarks

Management attributed the quarter’s margin gains and improving outlook to divestitures, investments in digital workflows, and rising demand for regulated testing from both biotech and large biopharma clients.

• DSA segment momentum: The DSA segment, focused on preclinical safety testing, saw its net book-to-bill ratio rise to nearly 1.2x for the third consecutive quarter, reflecting robust booking activity from both global pharmaceutical companies and smaller biotech firms. Management said this trend points to a pipeline of studies set to convert to revenue over the coming quarters.

• Divestitures streamlined operations: Recently completed divestitures of European discovery sites and the CDMO and Cell Solutions businesses helped sharpen the company’s focus on regulated testing. Management noted that these actions contributed to a 420 basis point sequential increase in operating margin, particularly benefiting the Manufacturing segment.

• AI and digital pathology investments: Charles River is investing in AI-enabled digital pathology solutions, designed to speed up study timelines and enhance efficiency for clients and internal teams. CEO Birgit Girshick described the new digital platform as a means to “cut at least one week from standard pathology timelines.”

• Nonhuman primate (NHP) supply integration: The company’s acquisition of breeding facilities in Cambodia and Mauritius improved supply security for NHPs, a critical resource for complex biologics safety studies. This integration is expected to yield lower sourcing costs and become a competitive advantage that supports market share gains in the DSA segment.

• China and academic segment pressures: While demand from Chinese biotech clients remained steady, management acknowledged ongoing weakness in North American academic and government-funded research due to flat National Institutes of Health (NIH) budgets and slower grant processing. This dynamic weighed on the Research Models and Services (RMS) segment, where revenue was down year over year.

Drivers of Future Performance

Charles River expects gradual acceleration in organic revenue growth and further margin expansion, driven by improved DSA bookings, operational efficiencies, and continued portfolio refinement.

• Biopharma funding tailwinds: Management pointed to near-peak trailing 12-month biotech funding and increased IPO activity as supporting stronger demand, especially from small and midsize clients. This funding environment is expected to sustain higher proposal volumes and bookings that feed future revenue.

• NHP supply and margin impact: The full financial benefit from integrated NHP sourcing will be realized in the fourth quarter, improving DSA operating margins as more studies transition to lower-cost, in-house supplied animals. CFO Glenn Coleman noted that this timing is due to the lag between animal importation and study initiation.

• Modernization and capacity expansion: Investments in AI-driven digital pathology and new bioanalytical laboratories, including a major expansion in Scotland, are intended to support future growth and efficiency. While these projects will not significantly affect 2026 revenue, management expects them to enhance competitiveness and utilization rates in 2027 and beyond.

Catalysts in Upcoming Quarters

In the coming quarters, our team will monitor (1) the pace at which DSA bookings convert to revenue, (2) realization of margin benefits from integrated NHP supply and Manufacturing segment improvements, and (3) progress on digital pathology and bioanalysis capacity expansions. We will also track whether the biopharma funding environment continues to bolster demand from smaller biotech clients, as well as signs of recovery in academic and government research spending.

Charles River Laboratories currently trades at $263.68, up from $234.12 just before the earnings. Is there an opportunity in the stock? Find out in our full research report (it’s free).

High Quality Stocks for All Market Conditions

ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.

Find out which 5 stocks it’s flagging this month — FREE. Get Our Top 5 Growth Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,552% between June 2020 and June 2025). Find your next big winner with StockStory today.